Molecular Imaging 2017

The PROMIS study

 576 men: MP-MRI followed by TRUS-& TPM-biopsy  408 (71%) had cancer; 230 (40%) clinically significant (G4+3)  Clinically significant cancer:  MP-MRI more SENSITIVE: 93% [95% CI 88-96%] vs TRUS- biopsy, 48% [42-55%]; p<0·0001  MP-MRI LESS specific: 41% [36-46%] for MP-MRI vs 96%, [94-98%] for TRUS-biopsy; p<0·0001)  44 (5·9%) of 740 patients reported serious adverse events, including 8 cases of sepsis

Ahmed HU et al. PROMIS study group. Lancet 2017;389(10071):815-822 Kapoor J et al. Eur Urol. 2017 Feb 23. pii: S0302-2838(17)30103-3.